authors
- Bug, G
- Burchert, A
- Wagner, E-M
- Kröger, N
- Berg, Tobias
- Güller, S
- Metzelder, SK
- Wolf, A
- Hünecke, S
- Bader, P
- Schetelig, J
- Serve, H
- Ottmann, OG
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- November 2017
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Adult (MeSH)
- Aged (MeSH)
- Antineoplastic Agents (MeSH)
- Female (MeSH)
- Hematopoietic Stem Cell Transplantation (MeSH)
- Histone Deacetylase Inhibitors (MeSH)
- Humans (MeSH)
- Hydroxamic Acids (MeSH)
- Immunology (Science Metrix)
- Indoles (MeSH)
- Leukemia, Myeloid, Acute (MeSH)
- Male (MeSH)
- Middle Aged (MeSH)
- Myelodysplastic Syndromes (MeSH)
- Panobinostat (MeSH)
- Young Adult (MeSH)
published in
- Leukemia Journal